期刊文献+

应用FRAX筛查骨质疏松高危人群的方法研究 被引量:6

Screening of high risk population of osteoporosis using FRAX method
暂未订购
导出
摘要 目的应用骨折风险评估工具(FRAX)预测不同骨质疏松性骨折危险因子及股骨颈骨密度(BMD)情况下10年骨折风险性的差异,探讨筛查骨质疏松高危人群的方法。方法应用FRAX的中国大陆子模型软件,综合年龄、性别、体重指数,计算单一危险因子或多重危险因子在联合或不联合BMD的条件下预测骨折风险性。结果随着BMD下降、骨折危险因子增多,10年骨质疏松性骨折风险增大。不同骨折危险因子和BMD配对时骨折风险性不同,当BMD未达骨质疏松诊断标准而合并部分危险因子时的骨折风险性大于BMD的T值达-2.5SD但无危险因子时的骨折风险性。结论 FRAX模型使原来单凭BMD转向综合各类危险因子评估长期骨质疏松性骨折风险性,在无条件行BMD检测地区可用以筛查骨质疏松高危人群。 Objective To predict different risk factors for osteoporotic fracture using fracture risk assessment (FRAX) tool and to predict 10-year fracture risk of the femoral neck with different bone mineral density (BMD) , and to explore screening methods for high risk group of osteoporosis. Methods Single or multiple risk factors combined with or without BMD were calculated using Chinese FRAX model, including age, gender, and body mass index. Results Fracture risk factors increased following the decrease of BMD. The risk of osteoporosis fracture increased in 10 years. The fracture risk was different in the combination of different fracture risk factors and BMD. The fracture risk was higher in BMD under the standard of osteoporosis diagnosis with partial risk factors than in BMD T value under - 2 ~ 5SD without risk factors. Conclusion FRAX model can evaluate long-term osteoporotic fracture risk rather than using BMD alone. It can screen the high risk population of osteoporosis in the area without BMD equipment.
出处 《中国骨质疏松杂志》 CAS CSCD 2011年第11期984-988,共5页 Chinese Journal of Osteoporosis
基金 安徽省卫生厅医学科研重点项目(编号:2010B006)
关键词 骨质疏松性骨折 危险因子 骨密度 骨折风险性 FRAX Osteoporotic fracture Risk factors Bone mineral density Fracture risk FRAX
  • 相关文献

参考文献17

  • 1Suhm N, Lamy O, Lippuner K. Management of fragility fractures in Switzerland: results of a nationwide survey. Swiss Med Wkly, 2008, 138:674-683.
  • 2Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. Osteoporos Int,2005, 16:581-589.
  • 3Kanis JA, Johansson H, Oden A, et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res, 2004, 19:893-899.
  • 4Siris ES, Miller PD, Barrett-Connor E, et al. Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA, 2001, 286:2815-2822.
  • 5van Staa T-P, Leufkens H-GM, Cooper C. Utility of medical and drug history in fracture risk prediction among men and women. Bone, 2002, 31:508-514.
  • 6van Staa T-P, Geusens P, Pols HA, et al. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. Quart J Med, 2005, 98:191-198.
  • 7Nguyen ND, Frost SA, Center JR, et al. Development of prognostic nomograms for ~ndividualizing 5-year and 10-year fracture risks. Osteoporos Int, 2008, 19 : 1431-1444.
  • 8Cummings SR, Black DM, Thompson DE, et al. Effect ofalendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. ~AMA, 1998, 280:2077-2082.
  • 9Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med, 2007, 356 : 1809-1822.
  • 10Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1 ~ 34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 2001, 344,1434-1441.

同被引文献68

引证文献6

二级引证文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部